Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer
Background: The Epstein-Barr virus (EBV) is intricately linked to a range of human malignancies, with EBV latent membrane protein 2A (LMP2A) emerging as a potential target antigen for immunotherapeutic strategies in the treatment of nasopharyngeal carcinoma (NPC). Methods: The modified vaccinia viru...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/52 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587713913552896 |
|---|---|
| author | Liying Sun Chao Liu Junping Peng |
| author_facet | Liying Sun Chao Liu Junping Peng |
| author_sort | Liying Sun |
| collection | DOAJ |
| description | Background: The Epstein-Barr virus (EBV) is intricately linked to a range of human malignancies, with EBV latent membrane protein 2A (LMP2A) emerging as a potential target antigen for immunotherapeutic strategies in the treatment of nasopharyngeal carcinoma (NPC). Methods: The modified vaccinia virus Ankara (MVA) is universally used in vector vaccine research because of its excellent safety profile and highly efficient recombinant gene expression. Here, we constructed a novel MVA-LMP2A recombinant virus and investigated its specific immune response induction and oncolytic effect. Results: An immunization dose of 2 × 10<sup>7</sup> PFU induced the highest specific immune response, which was no longer increased by boost injections after four doses. Three weeks post-final immunization, the specific immune response reached its peak. The MVA-LMP2A vaccine-induced LMP2A-specific cytotoxic T lymphocytes (CTLs), which exhibited substantial efficacy against target cells and effectively inhibited tumor growth. Conclusions: Thus, the MVA-LMP2A recombinant virus effectively induces strong LMP2A-specific cellular and humoral immune responses and anti-tumor activity. This work provides a promising therapeutic strategy for developing NPC candidate vaccines, as well as a reference for the treatment of EBV LMP2-associated malignancies. |
| format | Article |
| id | doaj-art-6c4788c2dfe444ddb4c9987d2b0ee520 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-6c4788c2dfe444ddb4c9987d2b0ee5202025-01-24T13:45:43ZengMDPI AGPharmaceutics1999-49232025-01-011715210.3390/pharmaceutics17010052Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal CancerLiying Sun0Chao Liu1Junping Peng2NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, ChinaState Key Laboratory of Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, ChinaNHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, ChinaBackground: The Epstein-Barr virus (EBV) is intricately linked to a range of human malignancies, with EBV latent membrane protein 2A (LMP2A) emerging as a potential target antigen for immunotherapeutic strategies in the treatment of nasopharyngeal carcinoma (NPC). Methods: The modified vaccinia virus Ankara (MVA) is universally used in vector vaccine research because of its excellent safety profile and highly efficient recombinant gene expression. Here, we constructed a novel MVA-LMP2A recombinant virus and investigated its specific immune response induction and oncolytic effect. Results: An immunization dose of 2 × 10<sup>7</sup> PFU induced the highest specific immune response, which was no longer increased by boost injections after four doses. Three weeks post-final immunization, the specific immune response reached its peak. The MVA-LMP2A vaccine-induced LMP2A-specific cytotoxic T lymphocytes (CTLs), which exhibited substantial efficacy against target cells and effectively inhibited tumor growth. Conclusions: Thus, the MVA-LMP2A recombinant virus effectively induces strong LMP2A-specific cellular and humoral immune responses and anti-tumor activity. This work provides a promising therapeutic strategy for developing NPC candidate vaccines, as well as a reference for the treatment of EBV LMP2-associated malignancies.https://www.mdpi.com/1999-4923/17/1/52Epstein-Barr virus latent membrane protein 2Amodified vaccinia virus ankaranasopharyngeal cancercytotoxic lymphocyteanti-tumor effect |
| spellingShingle | Liying Sun Chao Liu Junping Peng Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer Pharmaceutics Epstein-Barr virus latent membrane protein 2A modified vaccinia virus ankara nasopharyngeal cancer cytotoxic lymphocyte anti-tumor effect |
| title | Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer |
| title_full | Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer |
| title_fullStr | Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer |
| title_full_unstemmed | Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer |
| title_short | Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer |
| title_sort | specific immune responses and oncolytic effects induced by ebv lmp2a armed modified ankara vaccinia virus vectored vaccines in nasopharyngeal cancer |
| topic | Epstein-Barr virus latent membrane protein 2A modified vaccinia virus ankara nasopharyngeal cancer cytotoxic lymphocyte anti-tumor effect |
| url | https://www.mdpi.com/1999-4923/17/1/52 |
| work_keys_str_mv | AT liyingsun specificimmuneresponsesandoncolyticeffectsinducedbyebvlmp2aarmedmodifiedankaravacciniavirusvectoredvaccinesinnasopharyngealcancer AT chaoliu specificimmuneresponsesandoncolyticeffectsinducedbyebvlmp2aarmedmodifiedankaravacciniavirusvectoredvaccinesinnasopharyngealcancer AT junpingpeng specificimmuneresponsesandoncolyticeffectsinducedbyebvlmp2aarmedmodifiedankaravacciniavirusvectoredvaccinesinnasopharyngealcancer |